Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAY-069 是一种抑制剂。BAY-069对支链氨基酸转氨酶 1 (BCAT1)具有抑制作用(IC50:31 nM ,对支链氨基酸转氨酶 2 (BCAT2) 具有抑制作用(IC50 :153 nM)。BAY-069 是一种新型(三氟甲基)嘧啶二酮类化学探针, 可用于抗癌研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,290 | 现货 | ||
5 mg | ¥ 2,990 | 现货 | ||
10 mg | ¥ 4,390 | 现货 | ||
25 mg | ¥ 6,910 | 现货 | ||
50 mg | ¥ 9,490 | 现货 | ||
100 mg | ¥ 12,800 | 现货 | ||
500 mg | ¥ 25,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,260 | 现货 |
产品描述 | BAY-069 is an inhibitor. BAY-069 inhibited branched-chain amino acid transaminase 1 (BCAT1) at IC50:31 nM and branched-chain amino acid transaminase 2 (BCAT2) at IC50:153 nM. BAY-069 is a novel (trifluoromethyl) pyrimidine dione chemical probe, which can be used for anticancer research. |
靶点活性 | BCAT2:153 nM, BCAT1:31 nM |
体外活性 | BAY-069, inhibits the proliferation of U-87 and MDA-MB-231 cells. The compound is tested at concentrations ranging from 70 nM to 50 μM, with a duration of 72 hours. In U-87 cells, the IC50 is determined to be 358 nM, while in MDA-MB-231 cells, the IC50 is 874 nM [1]. |
体内活性 | BAY-069 demonstrates high metabolic stability when incubated with human liver microsomes, with a blood clearance of 0.11 L/h/kg. It also shows moderate metabolic stability when incubated with rat hepatocytes, with a blood clearance of 1.8 L/h/kg. BAY-069 exhibits high permeability through Caco-2 cell monolayers without any signs of efflux [1]. |
分子量 | 446.81 |
分子式 | C22H14ClF3N2O3 |
CAS No. | 2639638-66-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (61.55 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2381 mL | 11.1904 mL | 22.3809 mL | 55.9522 mL |
5 mM | 0.4476 mL | 2.2381 mL | 4.4762 mL | 11.1904 mL | |
10 mM | 0.2238 mL | 1.119 mL | 2.2381 mL | 5.5952 mL | |
20 mM | 0.1119 mL | 0.5595 mL | 1.119 mL | 2.7976 mL | |
50 mM | 0.0448 mL | 0.2238 mL | 0.4476 mL | 1.119 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BAY-069 2639638-66-5 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species BAY 069 BAY069 Inhibitor inhibitor inhibit